Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
A House bill aimed at getting more generic drugs on the market won’t be moving on a fast track to markup.
The legislation ( H.R. 749) is intended to lower drug prices by introducing more generic drug competition. Drugmakers are under heavy scrutiny by lawmakers, consumers, medical professionals and the president for their pricing practices.
The measure was introduced Jan. 30 by Reps. Gus Bilirakis (R- Fla.) and Kurt Schrader (D-Ore.). The sponsors and House Energy and Commerce Committee staff are working on a bipartisan basis to revise the bill before it is considered by the committee, a committee aide told Bloomberg BNA in a March 6 email.
The bill would require the Food and Drug Administration to prioritize and act on generic applications within 180 days of being filed for drug products that are in short supply or when there are too few manufacturers on the market. It also would increase transparency on the generic drug application backlog at the FDA.
“There are a group of drugs where there’s not a lot of competition where this could help expedite the review process if FDA would be able to meet that 180-day time clock,” David Rosen, an attorney with Foley & Lardner LLP in Washington, told Bloomberg BNA March 6. Rosen is the chair of the firm’s FDA regulatory practice and was employed at the FDA for 14 years.
However, some, including the head of the FDA’s drug center, don’t think a 180-day review period is possible.
The bill also would create a transferable priority review voucher that the FDA would award to a manufacturer that brings a generic drug to market when a branded product doesn’t have any competition.
Priority review vouchers exist for new branded drug products. Rosen said that for branded drug products, vouchers have “meant a lot of money,” mainly because these vouchers can be sold to other companies for a priority review of a different drug. Rosen is a Bloomberg BNA health-care advisory board member.
The bill was examined along with the FDA's generic drug and biosimilar user fee programs at a March 2 Energy and Commerce Health Subcommittee hearing.
Bloomberg Intelligence Analyst Brian Rye told Bloomberg BNA March 6 there’s a “very good chance” that H.R. 749 gets added to legislation that reauthorizes the generic drug user fee program.
Congress is preparing to consider legislation to reauthorize the laws governing industry-paid user fees that help fund the FDA. All four user fee programs—for prescription drugs, generic drugs, medical devices and biosimilars—expire Sept. 30. After that, new legislation will be needed to reauthorize the programs for fiscal years 2018 through 2022. The FDA and industry have already come up with agreements for reauthorizing the programs, which will serve as the basis for the legislation.
Whether the FDA could review a generic product within 180 days is unclear.
Allan Coukell, senior director for health programs at the Pew Charitable Trusts, said in his written testimony for the March 2 hearing “it is important to note that FDA already prioritizes generic applications when there is only one competing product on the market.”
“The net benefits and practical feasibility of a six-month review are unclear as is, consequently, the market value of a priority review voucher for generic applications,” Coukell said. “Perhaps more important than shortening the duration of review is reducing the number of review cycles.”
Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research (CDER), said at the hearing the agreement to reauthorize the Generic Drug User Fee Amendments, called GDUFA II, would require the agency to review priority generic drug applications within eight months of submission. Standard applications would be reviewed within 10 months.
Woodcock said the FDA can’t get too much quicker than an eight-month review, because the agency needs time to inspect the facilities where these products are made and some of the facilities are in foreign countries. When asked what Congress can do to help the FDA, she said it should pass GDUFA II.
To contact the reporter on this story: Bronwyn Mixter in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Brian Broderick at email@example.com
The bill is at http://src.bna.com/mMb.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)